ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Oct 05, 2022 19:55 JST
Source:
AIM Vaccine Co., Ltd.
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
To Commence Trading on the Main Board of the Hong Kong Stock Exchange on 6 October 2022
HONG KONG, Oct 05, 2022 - (ACN Newswire) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), today announced the allotment results of its Global Offering. The Offer Price is HK$16.16 per H share. Dealings in the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") are expected to commence on 6 October 2022 (Thursday) in board lot of 200 H shares each.
The H shares initially offered under the International Offering were over-subscribed. The net proceeds from the Global Offering are intended for advancing R&D of vaccine candidates and continuing to enrich vaccine pipeline, funding the capital expenditure on the construction of new production facilities for new vaccine products, and investing in sales and marketing activities. The Company said, through one decade of organic growth and external resource integration, AIM Vaccine has become a major player in the Chinese vaccine industry. The official listing on the Hong Kong Stock Exchange marks an important milestone in the history of the development of AIM Vaccine, opening a new chapter for the Company's development. The successful listing shows the trust and support of global investors for the Company's business development, and lays a firm ground for the Company's long-term growth. Looking forward, AIM Vaccine will carry on accelerating the R&D and commercialization process of the pipeline of vaccine candidates, and become a world-class vaccine company, thereby continuing to create greater value for shareholders.
Source: AIM Vaccine Co., Ltd.
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
Nov 08, 2024 10:31 JST
Hitachi High-Tech and University of Tokyo Promote Joint Research for the Practical Application of High-resolution Laser-PEEM in the Semiconductor Field
Nov 07, 2024 18:19 JST
Mitsubishi Motors Acquires Its Own Shares from Nissan
Nov 07, 2024 17:20 JST
Honda Signs Sponsorship Agreement to Provide Electrified Vehicles at World Athletics Championships Tokyo 25
Nov 07, 2024 17:10 JST
Home of Fujitsu joint conservation project designated as first Nationally Certified Sustainably Managed Natural Site in Okinawa
Nov 07, 2024 14:51 JST
NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting
Nov 07, 2024 11:40 JST
Anime Tokyo Station 1st Anniversary Event: Celebrating one year since the opening of the new hub for sharing Japanese anime
Nov 07, 2024 11:00 JST
57% of Banking Executives Struggle with Data Silos, Blocking AI-Driven Personalization, CleverTap's New Report Highlights
Nov 06, 2024 15:30 JST
Honda Unveils Electric Motorcycle Concept Models "EV Fun Concept" and "EV Urban Concept" at EICMA 2024
Nov 06, 2024 14:15 JST
Yoshimoto Kogyo and Mitsubishi Corporation have signed a business partnership agreement for co-creation of business using "laughter"
Nov 06, 2024 11:51 JST
Honda to Begin European Verification Test of Battery Sharing Service with GoCimo
Nov 06, 2024 10:39 JST
Honda Unveils World's First and New V3 Engine with Electrical- Compressor at EICMA 2024
Nov 06, 2024 09:03 JST
Victory and world title for TOYOTA GAZOO Racing
Nov 05, 2024 17:59 JST
Tokyo Stock Exchange and Fujitsu announce renewal of cash equity trading system 'arrowhead4.0'
Nov 05, 2024 17:13 JST
Mitsubishi Heavy Industries Continues Order Intake, Revenue, and Profit Growth in Strong First Half, Raises Full-Year Order Intake Guidance
Nov 05, 2024 14:37 JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 05, 2024 11:35 JST
Asahi Kasei and Honda Sign Shareholders' Agreement to Convert Existing Asahi Kasei Subsidiary into Joint Venture for Production of Lithium-ion Battery Separators in Canada
Nov 04, 2024 14:12 JST
Joby Aviation and Toyota Accelerate Efforts to Realize Air Mobility
Nov 04, 2024 09:36 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Nov 01, 2024 13:56 JST
All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024
Nov 01, 2024 12:43 JST
More Latest Release >>
Related Release
AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK
October 06 2022 19:16 JST
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
September 23 2022 17:06 JST
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
January 12 2022 10:26 JST
More Press release >>